Literature DB >> 21474628

Response assessment in neuro-oncology criteria: implementation challenges in multicenter neuro-oncology trials.

W B Pope, C Hessel.   

Abstract

Mesh：

Year:  2011        PMID： 21474628      PMCID： PMC7965568          DOI： 10.3174/ajnr.A2582

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN： 0195-6108            Impact factor:   3.825


× No keyword cloud information.
  4 in total

1.  Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group.

Authors:  Patrick Y Wen; David R Macdonald; David A Reardon; Timothy F Cloughesy; A Gregory Sorensen; Evanthia Galanis; John Degroot; Wolfgang Wick; Mark R Gilbert; Andrew B Lassman; Christina Tsien; Tom Mikkelsen; Eric T Wong; Marc C Chamberlain; Roger Stupp; Kathleen R Lamborn; Michael A Vogelbaum; Martin J van den Bent; Susan M Chang
Journal:  J Clin Oncol       Date:  2010-03-15       Impact factor: 44.544

2.  Response criteria for phase II studies of supratentorial malignant glioma.

Authors:  D R Macdonald; T L Cascino; S C Schold; J G Cairncross
Journal:  J Clin Oncol       Date:  1990-07       Impact factor: 44.544

Review 3.  Steroids in neurooncology: actions, indications, side-effects.

Authors:  Patrick Roth; Wolfgang Wick; Michael Weller
Journal:  Curr Opin Neurol       Date:  2010-12       Impact factor: 5.710

4.  Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.

Authors:  A D Norden; G S Young; K Setayesh; A Muzikansky; R Klufas; G L Ross; A S Ciampa; L G Ebbeling; B Levy; J Drappatz; S Kesari; P Y Wen
Journal:  Neurology       Date:  2008-03-04       Impact factor: 9.910
  4 in total
  20 in total

1.  Early post-bevacizumab progression on contrast-enhanced MRI as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 Central Reader Study.

Authors:  Jerrold L Boxerman; Zheng Zhang; Yair Safriel; Mykol Larvie; Bradley S Snyder; Rajan Jain; T Linda Chi; A Gregory Sorensen; Mark R Gilbert; Daniel P Barboriak
Journal:  Neuro Oncol       Date:  2013-06-19       Impact factor: 12.300

2.  Quantitative T2 mapping of recurrent glioblastoma under bevacizumab improves monitoring for non-enhancing tumor progression and predicts overall survival.

Authors:  Elke Hattingen; Alina Jurcoane; Keivan Daneshvar; Ulrich Pilatus; Michel Mittelbronn; Joachim P Steinbach; Oliver Bähr
Journal:  Neuro Oncol       Date:  2013-08-07       Impact factor: 12.300

Review 3.  Pros and cons of current brain tumor imaging.

Authors:  Benjamin M Ellingson; Patrick Y Wen; Martin J van den Bent; Timothy F Cloughesy
Journal:  Neuro Oncol       Date:  2014-10       Impact factor: 12.300

Review 4.  Radiographic read paradigms and the roles of the central imaging laboratory in neuro-oncology clinical trials.

Authors:  Benjamin M Ellingson; Matthew S Brown; Jerrold L Boxerman; Elizabeth R Gerstner; Timothy J Kaufmann; Patricia E Cole; Jeffrey A Bacha; David Leung; Amy Barone; Howard Colman; Martin J van den Bent; Patrick Y Wen; W K Alfred Yung; Timothy F Cloughesy; Jonathan G Goldin
Journal:  Neuro Oncol       Date:  2021-02-25       Impact factor: 12.300

5.  Prognostic value of contrast enhancement and FLAIR for survival in newly diagnosed glioblastoma treated with and without bevacizumab: results from ACRIN 6686.

Authors:  Jerrold L Boxerman; Zheng Zhang; Yair Safriel; Jeffrey M Rogg; Ronald L Wolf; Suyash Mohan; Helga Marques; A Gregory Sorensen; Mark R Gilbert; Daniel P Barboriak
Journal:  Neuro Oncol       Date:  2018-09-03       Impact factor: 12.300

Review 6.  Standardized MRI assessment of high-grade glioma response: a review of the essential elements and pitfalls of the RANO criteria.

Authors:  Dewen Yang
Journal:  Neurooncol Pract       Date:  2015-07-12

7.  On the promise of artificial intelligence for standardizing radiographic response assessment in gliomas.

Authors:  Benjamin M Ellingson
Journal:  Neuro Oncol       Date:  2019-11-04       Impact factor: 12.300

Review 8.  Evidence and context of use for contrast enhancement as a surrogate of disease burden and treatment response in malignant glioma.

Authors:  Benjamin M Ellingson; Patrick Y Wen; Timothy F Cloughesy
Journal:  Neuro Oncol       Date:  2018-03-27       Impact factor: 12.300

9.  Pseudoprogression in patients with glioblastoma: clinical relevance despite low incidence.

Authors:  Alexander Radbruch; Joachim Fladt; Philipp Kickingereder; Benedikt Wiestler; Martha Nowosielski; Philipp Bäumer; Heinz-Peter Schlemmer; Antje Wick; Sabine Heiland; Wolfgang Wick; Martin Bendszus
Journal:  Neuro Oncol       Date:  2014-07-18       Impact factor: 12.300

10.  Volumetric assessment of tumor size changes in pediatric low-grade gliomas: feasibility and comparison with linear measurements.

Authors:  Felice D'Arco; Patricia O'Hare; Fatima Dashti; Alvaro Lassaletta; Thalia Loka; Uri Tabori; Giacomo Talenti; Stefanie Thust; Giancarlo Messalli; Patrick Hales; Eric Bouffet; Suzanne Laughlin
Journal:  Neuroradiology       Date:  2018-01-30       Impact factor: 2.804
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.